Gamma delta (γδ) T cells are emerging as a transformative immunotherapy approach in oncology, offering unique mechanisms for targeting hematologic and solid tumors (I have written about clinical trials involving prostate cancer as well).
Unlike conventional αβ T cells, γδ T cells recognize stress-induced ligands on tumor cells, positioning them as key players in early cancer immune responses. Clinical trials have demonstrated promising results, particularly in acute myeloid leukemia (AML), where patients receiving γδ T cell therapies have shown 100% survival rates.
Moreover, γδ T cells offer long-term reconstitution and protection, making them an attractive option for durable cancer control. Their potential applications extend to solid tumors, such as glioblastoma, with encouraging early results in clinical studies.
Cancer at the cell level Peter Attia
